表紙
市場調查報告書

LanC樣蛋白2 (LanC Like Protein2):開發中產品分析

LanC Like Protein 2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 520777
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
LanC樣蛋白2 (LanC Like Protein2):開發中產品分析 LanC Like Protein 2 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 37 Pages
簡介

本報告提供以LanC樣蛋白2 (LanC Like Protein2)為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

LanC樣蛋白2 (LanC Like Protein2);概要

LanC樣蛋白2 (LanC Like Protein2);治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2207TDB

Summary

According to the recently published report 'LanC Like Protein 2 - Pipeline Review, H2 2019'; LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) pipeline Target constitutes close to 6 molecules.

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - LanC-like protein 2 is a protein encoded by the LANCL2 gene. It is important for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes.

The report 'LanC Like Protein 2 - Pipeline Review, H2 2019' outlays comprehensive information on the LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 5 respectively. Report covers products from therapy areas Immunology, Metabolic Disorders, Central Nervous System, Gastrointestinal and Oncology which include indications Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Crohn's Disease (Regional Enteritis), Lupus Erythematosus, Multiple Sclerosis, Systemic Lupus Erythematosus and Ulcerative Colitis.

Scope

  • The report provides a snapshot of the global therapeutic landscape for LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2)
  • The report reviews LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Overview
  • LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Companies Involved in Therapeutics Development
  • Landos Biopharma Inc
  • LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Drug Profiles
  • BT-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BT-11 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BT-111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BT-63 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BT-84 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NX-43 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Dormant Products
  • LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Product Development Milestones
  • Featured News & Press Releases
  • Aug 20, 2019: Landos Biopharma announces first patient dosed in global phase 2 trials of BT-11 in ulcerative colitis
  • May 15, 2019: Landos Biopharma announces publication of results from first-in-human phase 1 study of BT-11 in healthy volunteers
  • Mar 07, 2019: Landos Biopharma to present at upcoming investor conferences
  • Mar 05, 2019: Landos Biopharma Announces Publication of Results from Non-clinical Toxicity Studies Further Characterizing the Safety Profile of BT-11
  • Feb 21, 2019: Landos Biopharma announces publication supporting novel, dual mechanism of action for BT-11 in models of IBD
  • Jan 07, 2019: Landos Biopharma announces final safety results from phase 1 study of BT-11 in healthy volunteers
  • Jul 12, 2018: Landos doses first subject cohort in Phase l trial of BT-11 for IBD
  • Jun 05, 2018: Landos Biopharma Announces Human Translational Results for Mechanisms of BT-11 in IBD at Digestive Disease Week 2018
  • May 01, 2018: Mechanistic and Human Translational Results for BT-11 in Models of IBD
  • Jun 05, 2014: European Patent issued advancing Biotherapeutics' broad claims for treating and preventing Inflammation and Diabetes
  • May 19, 2014: BioTherapeutics awarded National Institutes of Health Small Business Innovation Research program award to advance novel therapy for IBD
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Landos Biopharma Inc, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type,, H2 2019
Back to Top